logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 7 of 7 Items
Showing 1 - 7 of 7 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Letter

Pediatric delamanid treatment for children with rifampicin-resistant TB

Tyeku N, Apolisi I, Daniels J, Beko B, Memani B,  et al.
2022-10-01 • International Journal of Tuberculosis and Lung Disease
2022-10-01 • International Journal of Tuberculosis and Lung Disease
Journal Blog
|
Perspective

Family matters: Why we need to do more for people affected by tuberculosis and their loved ones

Beko B, Furin J
2022-03-01 • PLoS Blogs
2022-03-01 • PLoS Blogs
Journal Article
|
Research

Implementing a substance-use screening and intervention program for people living with rifampicin-resistant tuberculosis: pragmatic experience from Khayelitsha, South Africa

Reuter A, Beko B, Memani B, Furin J, Daniels J,  et al.
2022-01-31 • Tropical Medicine and Infectious Disease
2022-01-31 • Tropical Medicine and Infectious Disease
Substance use (SU) is associated with poor rifampicin-resistant tuberculosis (RR-TB) treatment outcomes. In 2017, a SBIRT (SU screening-brief intervention-referral to treatment) was inte...
Journal Article
|
Research

DOT or SAT for Rifampicin-resistant tuberculosis? A non-randomized comparison in a high HIV-prevalence setting

Mohr E, Daniels J, Beko B, Isaakidis P, Cox V,  et al.
2017-05-18 • PLOS One
2017-05-18 • PLOS One
BACKGROUND
Daily directly-observed therapy (DOT) is recommended for rifampicin-resistant tuberculosis (RR-TB) patients throughout treatment. We assessed the impact of self-administer...
Journal Article
|
Commentary

Supporting families with tuberculosis during COVID-19 in Khayelithsa, South Africa

Apolisi I, Mema N, Tyeku N, Beko B, Memani B,  et al.
2022-03-01 • Lancet Respiratory Medicine
2022-03-01 • Lancet Respiratory Medicine
Journal Article
|
Research

Causes of loss to follow-up from drug-resistant TB treatment in Khayelitsha, South Africa

Memani B, Beko B, Dumile N, Mohr-Holland E, Daniels J,  et al.
2022-06-21 • Public Health Action
2022-06-21 • Public Health Action
Patients initiated on drug-resistant TB (DR-TB) treatment in 2019 in Khayelitsha, South Africa, with a loss to follow-up outcome were evaluated to better understand reasons for loss to f...
Journal Article
|
Letter

Correspondence regarding "Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa"

Mohr-Holland E, Reuter A, Hughes J, Daniels J, Beko B,  et al.
2020-07-01 • European Respiratory Journal
2020-07-01 • European Respiratory Journal